Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer

Withdrawn before enrolling · Phase 2

Conditions studied: PROSTATE CANCER

In brief

The main purpose of this study is to find out whether adding radiation therapy to the standard treatment of chemotherapy for prostate cancer is tolerated well and is more effective than the standard treatment of chemotherapy alone

Key facts

Study ID

NCT01087580

Run by

Northwestern University

People needed

0

Starts

2011-03-01

Expected to finish

2011-07-01

Last updated by the study team

2017-03-03

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have a diagnosis of castrate resistant prostate cancer.
• Participants must be 18 years old or older.
• Biopsy of tissue from the prostate or enlarged lymph nodes may be required.
• Patients must sign study specific informed consent prior to study entry.
• Men of child-producing potential must be willing to consent to use effective contraception while on treatment and for at least 3 months afterwards.

You may not qualify if…

• Participants cannot have prior chemotherapy for prostate cancer.
• Participants cannot have prior radiation therapy to the pelvis.

Where it is running

• Hematology Oncology Associates — Chicago, Illinois, United States
• Northwestern University, Northwestern Memorial Faculty Foundation — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.